NKMAX is a biotechnology company that develops immune cell therapy that can treat incurable human diseases, including cancer. They specialise in immune cells and provide immune healthcare solutions from diagnosis to treatment. They provide a precision immunodiagnostic kit that measures immunity based on research on NK cells.

Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., established on 2014-03-26, Business scope includes biological,Pharmaceutical technology development,technology transfer,technical consulting,Technical Services;Sales of biological reagents(Free of Hazardous Chemicals,medicine).(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Aposcience AG is a biopharmaceutical company established in 2008 and headquartered in Vienna.The company is developing innovative therapeutics for regenerative medicine that are based on secretomes of white blood cells isolated from peripheral blood. This approach sets Aposcience apart from the significant number of competitors working on stem cell based approaches. It is in tune with the generally accepted notion that stem cells exert their beneficial effects by paracrine signaling, not by rebuilding tissue per se. In contrast to competitors in the field, the company utilizes for APOSECTM production easily obtainable peripheral blood mononuclear cells as compared to stem cells or stem cell-derived secretomes from bone marrow.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Shanghai Bion Biomedical Technology Co., Ltd., established on 2007-03-27, Business scope includes licensed projects:Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Research and development of biomedicine and related products,Pharmaceutical Intermediates(In addition to drugs)research and development,Sales,transfer of own technology,And provide relevant technical services and technical advice,laboratory equipment,Chemical raw materials and products(In addition to dangerous goods,Monitor Chemicals,civilian explosives,precursor chemicals),Wholesale of instruments and meters,retail,First,Class II medical device sales,Engaged in the import and export of goods and technology.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.

DePuy Synthes Products, Inc. develops and markets medical products. It offers distal volar Radius, which is designed to treat distal radius fractures, dorsal endoplate, an invasive dorsal nail plate that provides fixed angle support and intramedullary locked fixation with a duplicate and reproducible surgical procedure, spatial subchondral support plate, which is used to treat proximal humeral fractures and Small Bone Fixation System, a percutaneous locked intramedullary nail system for metacarpals and the phalanges. The company was founded on June 22, 2004 and is headquartered in Wilmington, DE.

GI CELL Co. Ltd. is a South Korean company located in Seongnam that develops cell therapeutics. The firm was founded in 2018 by Myoung Ho Jang. Chun Pyo Hong is the current CEO of the company.\nThe company says this about itself: GI CELL is a biotechnology company that drives research and development of novel immune cell-based therapies with innovative technologies. Using its proprietary Immune CellPURE Expander® platform for highly potent NK and T cell development, GI CELL has integrated its ancillary material screening and cell expansion technologies to streamline the entire cell product development process. The Company is advancing its allogenic NK cell therapies to transform the treatment paradigm for patients with hematological malignancies and solid tumors. GI CELL has multiple NK cell product candidates in IND-enabling and preclinical development.

PBD Biotech is a clinical-stage diagnostic company and pioneer in phage-based diagnostics. PBD is focused on the development of Actiphage for the detection of tuberculosis in latent TB screening and drug management.

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. The firm involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

Savicell provides a blood test platform for the early detection and identification of disease. The company's Well-Shield platform applies metabolomics to immune responses in cancer, infections, and other disorders for early and accurate diagnosis.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.